Skip to main content

Our Outputs

Our Outputs

Publications

Time, pattern and outcome of medulloblastoma relapse are associated with tumour biology at diagnosis and therapy: A multi-centre cohort study. Hill RM, Richardson S, Schwalbe EC, Hicks D, Lindsey JC, Crosier S, Rafiee G, Grabovska Y, Wharton SB, Jacques TS , Michalski A, Joshi A, Pizer B, Williamson D, Bailey S, Clifford SC (2020). The Lancet Child and Adolescent Health. In press.

The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes. Hicks D, Rafiee G, Schwalbe EC, Howell CI, Lindsey JC, Hill RM, Smith AJ, Adidharma P, Steel C, Richardson S, Pease L, Danilenko M, Crosier S, Joshi A, Wharton SB, Jacques TS, Pizer B, Michalski A, Williamson D, Bailey S, Clifford SC (2020). Neuropathol Appl Neurobiol. Epub ahead of print. PMID:32779246.

Liver Cancer research

Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Grabovska Y, Mackay A, O'Hare P, Crosier S, Finetti M, Schwalbe EC, Pickles JC, Fairchild AR, Avery A, Cockle J, Hill R, Lindsey J, Hicks D, Kristiansen M, Chalker J, Anderson J, Hargrave D, Jacques TS, Straathof K, Bailey S, Jones C, Clifford SC, Williamson D (2020). Nat Commun. 2020. 11(1):4324. PMID: 32859926.

Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus. Ho B, Johann PD, Grabovska Y, De Dieu Andrianteranagna MJ, Yao F, Frühwald M, Hasselblatt M, Bourdeaut F, Williamson D, Huang A, Kool M. Neuro Oncol. 2020 May 15;22(5):613-624. doi: 10.1093/neuonc/noz235. PMID: 31889194.

Translational genomics of malignant rhabdoid tumours: Current impact and future possibilities. Finetti MA, Grabovska Y, Bailey S, Williamson D. Semin Cancer Biol. 2020 Apr;61:30-41. doi: 10.1016/j.semcancer.2019.12.017. Epub 2020 Jan 7. PMID: 31923457.

Medulloblastoma. Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, Rutkowski S, Ellison DW, Malkin D, Taylor MD, Gajjar A, Pfister SM (2019). Nature Reviews Disease Primers. 14:11 PMID: 30765705.

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Sharma T, Schwalbe EC, Williamson D, Sill M, Hovestadt V, Mynarek M, Rutkowski S, Robinson GW, Gajjar A, Cavalli F, Ramaswamy V, Taylor MD, Lindsey JC, Hill RM, Jäger N, Korshunov A, Hicks D, Bailey S, Kool M, Chavez L, Northcott PA, Pfister SM, Clifford SC (2019). Acta Neuropathol. 138: 309-326. PMID: 31076851. Open Access.

Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. Erkek S, Johann PD, Finetti MA, Drosos Y, Chou HC, Zapatka M, Sturm D, Jones DTW, Korshunov A, Rhyzova M, Wolf S, Mallm JP, Beck K, Witt O, Kulozik AE, Frühwald MC, Northcott PA, Korbel JO, Lichter P, Eils R, Gajjar A, Roberts CWM, Williamson D, Hasselblatt M, Chavez L, Pfister SM, Kool M.Cancer Cell. 2019 Jan 14;35(1):95-110.e8. PMID: 30595504. Open Access.

EANO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up of post-pubertal and adult patients with medulloblastoma. Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann R, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Guerreiro Stucklin AS, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P (2019). The Lancet Oncology. 12: e715-728. PMID: 30595504.

Prognostic impact of whole chromosomal aberration signatures in standard-risk non-WNT/non-SHH medulloblastoma: A retrospective molecular analysis of the HIT-SIOP-PNET4 clinical trial. Goschzik T, Schwalbe EC, Hicks D, Smith A, zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC (2018). The Lancet Oncology. 19: 1602-1616. PMID: 30392813. Open Access.

Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures. Schwalbe EC, Hicks D, Rafiee G, Bashton M, Gohlke H, Enshaei A, Potluri S, Matthiesen J, Mather M, Taleongpong P, Chaston R, Silmon A, Curtis A, Lindsey JC, Crosier S, Smith AJ, Goschzik T, Doz F, Rutkowski S, Lannering B, Pietsch T, Bailey S, Williamson D, Clifford SC (2017). Sci Rep. 7: 13421. PMID: 29044166. Open Access.

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: A cohort study. Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC (2017). The Lancet Oncology. 18: 958-971. PMID: 28545823. Open Access.

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Hill RM, Kuijper S, Lindsey JC, Petrie K…Michalski A, Hargrave D, Jacques TS, Pizer B, Bailey S, Swartling FJ, Weiss WA, Chesler L, Clifford SC (2015). Cancer Cell. 27: 72-84. PMID: 25533335. Open Access.

Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance. Lindsey JC, Kawauchi D, Schwalbe EC, Solecki DJ, Selby MP, McKinnon PJ, Olson JM, Hayden JT, Grundy RG, Ellison DW, Williamson D, Bailey S, Roussel MF, Clifford SC (2015). Oncogene. 34: 4746-57. PMID: 25531316.

TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours. Lindsey JC, Schwalbe EC, Potluri S, Bailey S, Williamson D, Clifford SC (2014). Acta Neuropathol. 127: 307-9. PMID: 24337442.

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors. Bull KS, Kennedy CR, Bailey S, Ellison DW, Clifford SC (2014). Acta Neuropathol. 128: 151-3. PMID: 24879579.

DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL....Taylor RE, Ellison DW, Bailey S, Clifford SC (2013). Acta Neuropathol. 125: 359-71. PMID: 23291781.

Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Schwalbe EC, Hayden JT, Rogers HA, Miller S, Lindsey JC, Hill RM, Nicholson SL, Kilday JP, Adamowicz-Brice M, Storer L, Jacques TS, Robson K, Lowe J, Williamson D, Grundy RG, Bailey S, Clifford SC (2013). Acta Neuropathol. 126: 943-6. PMID: 24212602.

Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Northcott PA, Shih DJ….Rutka JT, Malkin D, Clifford SC, Jones SJ, Korbel JO, Pfister SM, Marra MA, Taylor MD (2012). Nature. 488: 49-56. PMID: 22832581.

Molecular subgroups of medulloblastoma: the current consensus. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012). Acta Neuropathol. 123: 465-72. PMID: 22134537.

Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. Lannering B, Rutkowski S, Doz F….Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R (2012). Journal of Clinical Oncology. 30: 3187-93. PMID: 22851561.

Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Ellison DW, Dalton J….Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ (2011). Acta Neuropathol 121: 381-396. PMID: 21267586.

Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC (2011). Journal of Clinical Oncology. 29: 1400-1407. PMID: 20921458.

Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsić A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R. (2008). PLoS ONE. 3: e3088. PMID: 18769486. Open Access.

Wnt/Wingless pathway activation and chromosome 6 loss characterise a distinct molecular sub-group of medulloblastomas associated with a favourable prognosis. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ Straughton D, Ellison DW. (2006). Cell Cycle. 5: 2666-2670. PMID: 17172831. Open Access.

Beta-catenin status predicts a favorable outcome in childhood medulloblastoma. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC (2005). Journal of Clinical Oncology. 23: 7951-7. PMID: 16258095.